Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 2

Treating psoriasis with adalimumab

Authors Eihab A Alwawi, Stephanie L Mehlis, Kenneth B Gordon

Published 11 April 2008 Volume 2008:4(2) Pages 345—351

DOI https://doi.org/10.2147/TCRM.S1265

Eihab A Alwawi1, Stephanie L Mehlis1, Kenneth B Gordon1,2

1Division of Dermatology and Department of Medicine, Evanston Northwestern Healthcare, Skokie, IL, USA; 2Department of Dermatology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA

Abstract: Psoriasis is a common, chronic, inflammatory skin disease that can have a significant impact on the quality of life of those who are afflicted. Recent advances in the understanding of the pathophysiology of psoriasis have led to the development of new, genetically engineered, targeted therapies for this disease. Among the most successful strategies for treatment has been the use of biologic immunotherapies targeting tumor necrosis factor alpha (TNF). Recent research has evaluated the efficacy and safety of a new anti-TNF agent, adalimumab. Adalimumab is a human monoclonal antibody that is approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) for the treatment of rheumatoid arthritis and psoriatic arthritis. Recently released data from large, randomized clinical trials suggests that adalimumab has significant efficacy for the treatment of chronic plaque psoriasis and is well tolerated. Thus, adalimumab seems to be a promising therapeutic approach for patients who suffer from moderate to severe plaque psoriasis.

Keywords: psoriasis, adalimumab, tumor necrosis factor alpha

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Erratum

Marusza W, Mlynarczyk G, Olszanski R, Netsvyetayeva I, Obrowski M, Iannitti T, Palmieri B

International Journal of Nanomedicine 2012, 7:4119-4120

Published Date: 27 July 2012

Nimodipine-loaded mixed micelles: formulation, compatibility, pharmacokinetics, and vascular irritability study

Song X, Jiang Y, Ren CJ, Sun X, Zhang Q, Gong T, Zhang ZR

International Journal of Nanomedicine 2012, 7:3689-3699

Published Date: 13 July 2012

Intrathecal bupivacaine for head and neck pain

Shawn A Belverud, Alon Y Mogilner, Michael Schulder

Local and Regional Anesthesia 2010, 3:125-128

Published Date: 11 October 2010

Tolvaptan and its potential in the treatment of hyponatremia

Megan B Dixon, Y Howard Lien

Therapeutics and Clinical Risk Management 2008, 4:1149-1155

Published Date: 5 December 2008

Association between homocysteinemia and metabolic syndrome in patients with cardiovascular disease

Chiara Bellia, Giulia Bivona, Concetta Scazzone, Marcello Ciaccio

Therapeutics and Clinical Risk Management 2007, 3:999-1001

Published Date: 15 January 2008